

## **National Cancer Institute**

### **Clinical Trials Planning Meeting on Improving Management of Small Renal Masses and Early Stage Renal Cell Carcinoma**

**NIH Campus, Bethesda, Maryland, January 23-24, 2020**

**Workshop Co-Chairs: Janice Dutcher, M.D., Michael Jewett, M.D. and Sabina Signoretti, M.D.**

#### **Introduction and Background**

The National Cancer Institute organized a Clinical Trials Planning Meeting (CTPM) on Improving Management of Small Renal Masses (SRMs) and Early Stage Renal Cell Carcinoma in an effort by the Renal Task Force of the NCI Genitourinary Steering Committee. This CTPM occurred on January 23-24, 2020, at the NIH Main Campus in Bethesda (Maryland). It was chaired by Drs. Janice Dutcher, Michael Jewett, and Sabina Signoretti, and assembled leaders in the field to share scientific insights and identify emerging opportunities in basic, translational and clinical research.

The goals of the meeting were to advance the state-of-the-science to address the scientific and clinical questions related to SRM, to improve pre-treatment ability to predict clinical behavior, i.e., the likely clinical course of the SRM in the patient to individualize treatment. Experts in this meeting focused on: (i) designing clinical trials with objectives of correlating advanced imaging parameters (findings) with tumor biology, pathology and subsequent clinical course, to define imaging biomarker(s); (ii) correlating molecular analysis of tumor tissue obtained by renal mass biopsy with clinical course to define tumor tissue-based biomarker.

Potential deliverables of this CTPM include:

1. Proposal for 1 or more clinical trial concepts that will correlate advanced imaging findings and tissue-based molecular analysis to improve the certainty of diagnosis prior to definitive treatment of an individual patient.
2. One or more clinical trial concepts for treatment of localized renal masses and T1 tumors including extent of surgery (partial vs radical nephrectomy and ablation technologies).
3. A report addressing the uncertainties in the evaluation and management of renal mass including the design of a master protocol or trial to address them, including defining optimal tissue handling and banking for studies of kidney cancer and other renal mass histologies, natural history and response to treatment.


## **Summary of Discussions Leading to Action Plans for Addressing the Scientific and Clinical Challenges**

The CTPM included four working groups who joined their expertise to address research questions on how to reduce SRM overtreatment by avoiding unnecessary intervention for benign or indolent disease, identifying the best treatment strategies based on a risk-stratified approach to management combined with an optimal follow-up, and assessing the cost of SRM management both at an institutional and individual patient levels. A number of clinical trial designs were considered and discussed, with several approaches focusing on evaluation of pre-treatment biopsy to guide clinical decision towards active surveillance or intervention that could generate data in the context of exploring novel endpoints including intervention free survival.

Participants within the scientific sessions covered the scope of the problem, discussed substantive strategies to explore biopsy information, the extent of resection, and the rates of local progression-free survival and systemic therapy-free survival, in the context of active surveillance versus intervention.

A number of substantive and collaborative ideas were generated as direct outcomes of this CTPM leading to a focus group including clinicians and statisticians that are joining their efforts in organizing the next steps of this endeavor by providing specific information on endpoints, sample size, power calculation and feasibility of clinical trials under consideration.

***This Executive Summary presents the consensus arising from the Clinical Trials Planning Meeting. These action plans are not meant to address all clinical contexts, but rather represent priorities for publicly funded clinical research.***



NCI – Genitourinary Steering Committee – Renal Task Force

Clinical Trial Planning Meeting

Improving Management of Small Renal Masses

and Early Stage Renal Cell Carcinoma

Meeting Agenda

January 23 – 24, 2020

NIH Main Campus | Building 45 | Natcher Conference Center

45 Center Drive | Bethesda, Maryland 20892

Thursday, January 23, 2020

8:00 AM – 8:05 AM NCI Welcome

8:05 AM – 8:10 AM Welcome and Overview of Goals for the Workshop

Jan Dutcher, Michael Jewett,

Sabina Signoretti

Session1: The Challenges of Small Renal Mass (SRM) and Renal Cysts Suspicious for Malignancy

Chair: Hyung Kim

8:10 AM – 9:20 AM Session 1: The Challenges of Small Renal Mass (SRM) & Renal Cysts Suspicious for Malignancy

Hyung Kim

Urological Perspective

Robert Uzzo

Imaging Perspective

Ivan Pedrosa

Pathology Perspective

Sabina Signoretti

“Use of Biopsy”

Victor Reuter

“Use of Diagnostic Biomarkers”

Payal Kapur

Challenges from Patient and Caregiver Perspectives

Deb Maskens

9:20 AM – 9:40 AM Q&A – Discussion

9:40 AM – 9:55 AM

*Break*

**Session 2: Endpoints and Clinical Trial Design**

**Session Chair: Brian Shuch**

9:55 AM – 11:25 AM

Introduction

*Brian Shuch*

Development of Surrogate Endpoints and Relevance to Early Stage Cancer

*Sundeep Agrawal*

Traditional Clinical Trial Endpoints: Sample Size, Power, Bias Challenges

*Susan Halabi*

Comparing Treatment Modalities Using PROs: How and When Appropriate

*Paul Kluetz*

Traditional and Novel Radiologic Imaging Endpoints Relevant to Kidney Cancer

*Andrew Smith*

Comparing Ablative Modalities: Pathologic Consideration

*Chris Trindade*

Diagnostic/Predictive/Prognostic Molecular Biomarkers and Role of Utility

*Anand Pathak*

Functional Renal Endpoints for Kidney Cancer: Considering Surgical CKD

*Bill Huang*

Discussion

**Session 3: Barriers to Conducting Trials in the Management of SRM and Lessons Learned from other Early Stage Diseases**

**Session Chair: Antonio Finelli**

11:25 AM – 12:30 PM

Introduction

*Antonio Finelli*

Challenges in clinical trials

*Barry Kramer*

Title TBD

*Axel Bex*

Title TBD

*Maxine Tran*

12:30 PM – 1:30 PM

*Lunch*

**Overview Master Concept for SRM Trials and Breakouts**

1:30 PM – 1:45 PM

Overview Master Concept for SRM Trials

*Gennady Bratslavsky*

*Breakouts*

1:45 PM – 2:45 PM

Working Groups will address the major ‘challenge’ questions key to trial concepts.

Preselected groups, with mix of expertise, will address one question each and will potentially work together for the rest meeting to develop and own a concept

***Breakouts Group Questions***

1. How to reduce SRM overtreatment – “Who to Treat”
  - a. How do we determine which SRMs and complex renal cystic masses suspicious for malignancy need treatment (as both have heterogeneous biology in terms of potential for growth and metastasis)? To include, what is the:
    - i. Role for biopsy (usually needle biopsy)
    - ii. Role for biomarkers including imaging – virtual biopsy (serum, urine, tissue), functional imaging – also role for SRM detection and surveillance on and after treatment
2. What is the best treatment – “How to Treat”
  - a. What is the best SRM treatment? – surgery (PN vs RN), ablations (RFA, Cryo, SBRT), active surveillance (AS)
3. What is the best follow-up – “Follow-up”
  - a. How should we follow patients on surveillance for SRM/complex renal cystic mass and after treatment? Type, frequency of imaging, role biomarkers, etc.
4. What is the ‘cost’ of SRM management – “Cost”
  - a. What is the impact of diagnostic and treatment uncertainties on patient anxiety? QOL, economics, decision making and compliance? Role of PRO’s and other? Health economics.

**2:45 PM – 3:00 PM**

***Break***

**3:00 PM – 4:00 PM**

***Report Out by Breakout Groups***

**Session 5 (Part A): Moving Forward – Trial Concepts Town Hall**

**Session Chair: Gennady Bratslavsky**

**4:00 PM – 6:00 PM** Trial Concepts Town Hall

**Friday, January 24, 2020**

**Session 5 (Part B): Moving Forward – Trial Concepts Discussion and Consensus**

**Session Chair: Gennady Bratslavsky**

**8:00 AM – 11:30 AM** Trial Concepts discussion and consensus


Objective: Design one or more clinical trial(s) the for management of SRM

**11:30 AM – 12:00 PM**

Summary, Next Steps, Recommendations, and Closing Remarks

**12:00 PM**

*Adjourn*



**NCI – Genitourinary Steering Committee – Renal Task Force  
Clinical Trial Planning Meeting**

**Improving Management of Small Renal Masses  
and Early Stage Renal Cell Carcinoma**

**Meeting Participant List  
January 23 – 24, 2020**

**Sundeep Agrawal, M.D.**

U.S. Food and Drug Administration  
Silver Spring, MD

**Gennady Bratslavsky, M.D.**

SUNY Upstate Medical University  
Syracuse, NY

**Mark Ball, M.D.**

National Cancer Institute  
Bethesda, MD

**Michael Brown, M.D.**

U.S. Food and Drug Administration  
Silver Spring, MD

**Naomi Balzer Haas, M.D.**

Abramson Cancer Center  
Philadelphia, PA

**James Brugarolas, M.D., Ph.D.**

UT Southwestern Medical Center  
Dallas, TX

**Dena Battle**

KCCure  
Alexandria, VA

**Steven Campbell, M.D., Ph.D.**

Cleveland Clinic  
Cleveland, OH

**Cristiane Decat Bergerot, Ph.D.**

City of Hope Comprehensive Cancer Center  
Monrovia, CA

**Brian Costello, M.D., M.S.**

Mayo Clinic  
Rochester, MN

**Carolyn Best, Ph.D.**

American Urological Association  
Linthicum, MD

**James Dignam, Ph.D.**

University of Chicago  
Chicago, IL

**Axel Bex, M.D., Ph.D.**

Royal Free London NHS Foundation Trust  
London, United Kingdom

**Jeremy Durack, M.D., M.S.**

Memorial Sloan Kettering Cancer Center  
New York, NY

**Rupal Bhatt, M.D., Ph.D.**

Beth Israel Deaconess Medical Center  
Harvard Medical School  
Roslindale, MA

**Janice Dutcher, M.D.**

Cancer Research Foundation  
Bronx, NY

**Rodney Ellis, M.D.**

PSH Milton Hershey Medical Center  
Hershey, PA

**Antonio Finelli, M.D., M.Sc.**

Princess Margaret Cancer Centre  
Toronto, ON

**Jared Foster, Ph.D.**

National Cancer Institute  
Rockville, MD

**Boris Gershman, M.D.**

Beth Israel Deaconess Medical Center  
Boston, MA

**Debra Gottsleben, M.A., Ed.S.**

KCCure  
Morristown, NJ

**Ari Hakimi, M.D.**

Memorial Sloan Kettering Cancer Center  
New York, NY

**Susan Halabi, Ph.D.**

Duke University  
Durham, NC

**Raquibul Hannan, M.D., Ph.D.**

UT Southwestern Medical Center  
Dallas, TX

**Brandy Heckman-Stoddard, Ph.D., M.P.H.**

National Cancer Institute  
Rockville, MD

**William Huang, M.D.**

NYU Langone Health  
New York, NY

**Erich Huang, Ph.D.**

National Cancer Institute  
Rockville, MD

**Deborah Jaffe, Ph.D.**

National Cancer Institute  
Rockville, MD

**Michael Jewett, M.D.**

Princess Margaret Cancer Centre  
University of Toronto  
Toronto, ON

**Eric Jonasch, M.D.**

UT MD Anderson Cancer Center  
Houston, TX

**Anil Kapoor, M.D.**

St. Joseph's Healthcare, Hamilton  
Hamilton, Ontario, Canada

**Payal Kapur, M.D.**

University of Texas Southwestern Medical  
Center  
Dallas, TX

**William Kelly, D.O.**

Thomas Jefferson University  
Philadelphia, PA

**Hyung Kim, M.D.**

Cedars-Sinai Medical Center  
Los Angeles, CA

**Paul Kluetz, M.D.**

U.S. Food and Drug Administration  
Silver Spring, MD

**Barry Kramer, M.D., M.P.H.**

National Cancer Institute (Retired)

**Igor Kuzmin, Ph.D.**

National Cancer Institute  
Rockville, MD

**Seth Lerner, M.D.**

Baylor College of Medicine  
Houston, TX

**Bryan Lewis, J.D.**

Kidney Cancer Coalition, Inc.  
Philadelphia, PA

**W. Marston Linehan, M.D.**

National Cancer Institute  
Bethesda, MD



**Bhupinder Mann, M.B.B.S.**  
National Cancer Institute  
Rockville, MD

**Deborah Maskens, M.A., M.S.M.**  
International Kidney Cancer Coalition  
Guelph, Ontario, Canada

**Worta McCaskill-Stevens, M.D.**  
National Cancer Institute  
Bethesda, MD

**Michael A. McDonald, M.D., Ph.D.**  
National Cancer Institute  
Bethesda, MD

**Lisa McShane, Ph.D.**  
National Cancer Institute  
Bethesda, MD

**Lori Minasian, M.D.**  
National Cancer Institute  
Bethesda, MD

**Afshin Parsa, M.D., M.P.H.**  
National Institute of Diabetes and Digestive and  
Kidney Diseases  
Bethesda, MD

**Anand Pathak, M.D., Ph.D.**  
U.S. Food and Drug Administration  
Silver Spring, MD

**Ivan Pedrosa, M.D., Ph.D.**  
UT Southwestern Medical Center  
Dallas, TX

**Victor Reuter, M.D.**  
Memorial Sloan Kettering Cancer Center  
New York, NY

**Patrick Richard, M.D., M.Sc.**  
Université de Sherbrooke  
Sherbrooke, Quebec, Canada

**Sandra Russo, M.D., Ph.D., M.P.H.**  
National Cancer Institute  
Bethesda, MD

**Lalitha Shankar, M.D., Ph.D.**  
National Cancer Institute  
Rockville, MD

**Brian Shuch, M.D.**  
Ronald Reagan UCLA Medical Center  
Los Angeles, CA

**Sabina Signoretti, M.D.**  
Brigham and Women's Hospital  
Boston, MA

**Stuart Silverman, M.D.**  
Brigham and Women's Hospital/Harvard Medical  
School  
Boston, MA

**Eric Singer, M.D., M.A., M.S., F.A.C.S.**  
Rutgers Cancer Institute of New Jersey  
New Brunswick, NJ

**Andrew Smith, M.D.**  
University of Alabama Birmingham  
Birmingham, AL

**Michael Staehler, M.D., Ph.D.**  
University of Munich  
München, Germany

**Abdul Tawab Amiri, Ph.D.**  
National Cancer Institute  
Rockville, MD

**Maxine Tran, M.B.B.S., Ph.D., F.R.C.S.**  
Royal Free Hospital  
London, United Kingdom

**Christopher Trindade, M.D.**  
U.S. Food and Drug Administration  
Bethesda, MD

**Robert G. Uzzo, M.D. M.B.A.**  
Temple, Fox Chase Cancer Center  
Philadelphia, PA

**Ulka Vaishampayan, M.D.**  
Karmanos Cancer Institute  
Detroit, MI

**Pamela West**  
Emmes Corporation  
Rockville, MD

**Nicholas Zaorsky, M.D.**  
Penn State College of Medicine  
Hershey, PA